Heron Therapeutics, Inc. (HRTX) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	151.2M	154.9M	144.3M	127.0M	107.7M
Cost of Revenue	45.2M	41.3M	38.6M	65.1M	54.9M
Gross Profit	105.9M	113.6M	105.6M	61.9M	52.8M
Operating Expenses
R&D Expense	12.3M	12.4M	16.7M	39.1M	82.7M
SG&A Expense	104.5M	103.7M	100.5M	119.8M	144.8M
General & Admin Expense	50.9M	54.6M	53.4M	58.5M	62.2M
Selling & Marketing Expense	53.6M	49.1M	47.1M	61.3M	82.5M
Other Expenses	—	—	—	13.6M	—
Total Operating Expenses	116.8M	116.1M	117.2M	172.6M	227.5M
Cost and Expenses	162.0M	157.4M	155.8M	237.7M	282.3M
Operating Income (EBIT)	(10.9M)	(2.5M)	(11.5M)	(110.6M)	(174.7M)
Non-Operating
Interest Income	—	—	3.5M	3.4M	1.6M
Interest Expense	3.9M	—	6.0M	3.9M	2.5M
Net Interest Income	(3.9M)	—	(2.5M)	(504.0K)	(836.0K)
Other Non-Op Income/Expense	(23.2M)	(17.7M)	(2.1M)	56.0K	(7.4M)
Non-Operating Income (excl Interest)	19.3M	17.7M	(4.0M)	(3.9M)	4.9M
EBT (Pre-Tax Income)	(34.0M)	(20.2M)	(13.6M)	(110.6M)	(182.0M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(34.0M)	(20.2M)	(13.6M)	(110.6M)	(182.0M)
Earnings from Cont. Ops	(34.0M)	(20.2M)	(13.6M)	(110.6M)	(182.0M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(34.0M)	(20.2M)	(13.6M)	(110.6M)	(182.0M)
Per Share
Basic EPS	($0.19)	($0.12)	($0.09)	($0.80)	($1.67)
Diluted EPS	($0.19)	($0.12)	($0.09)	($0.80)	($1.67)
Revenue Per Share	$0.79	$0.93	$0.95	$0.92	$0.99
Shares
Basic Shares Outstanding	190.3M	166.7M	152.4M	138.1M	109.0M
Diluted Shares Outstanding	190.3M	166.7M	152.4M	138.1M	109.0M
Profitability Metrics
EBITDA	(27.8M)	(17.9M)	(5.1M)	(103.8M)	(176.7M)
D&A	2.3M	2.3M	2.5M	2.9M	2.9M
EBIT	(30.1M)	(20.2M)	(7.5M)	(106.7M)	(179.6M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026